IFNA1 and myeloid sarcoma: More than 94% of MS patients who completed the core OPERA I and II trials were enrolled in an OLE phase of 3 years, during which patients previously treated with ocrelizumab continued the treatment, whereas those treated with IFN switched to ocrelizumab 600 mg every 24 weeks (70).